186 related articles for article (PubMed ID: 31896813)
21. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
22. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
23. OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
Ge X; Peng X; Li M; Ji F; Chen J; Zhang D
Pathol Res Pract; 2021 Sep; 225():153580. PubMed ID: 34391182
[TBL] [Abstract][Full Text] [Related]
24. O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1.
Zhu Q; Zhou H; Wu L; Lai Z; Geng D; Yang W; Zhang J; Fan Z; Qin W; Wang Y; Zhou R; Yi W
Nat Chem Biol; 2022 Oct; 18(10):1087-1095. PubMed ID: 35879546
[TBL] [Abstract][Full Text] [Related]
25. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.
Lynch TP; Ferrer CM; Jackson SR; Shahriari KS; Vosseller K; Reginato MJ
J Biol Chem; 2012 Mar; 287(14):11070-81. PubMed ID: 22275356
[TBL] [Abstract][Full Text] [Related]
26. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
27.
Nakamoto A; Ohashi N; Sugawara L; Morino K; Ida S; Perry RJ; Sakuma I; Yanagimachi T; Fujita Y; Ugi S; Kume S; Shulman GI; Maegawa H
Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E46-E61. PubMed ID: 37224467
[TBL] [Abstract][Full Text] [Related]
28. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
29. Diverse metabolic effects of O-GlcNAcylation in the pancreas but limited effects in insulin-sensitive organs in mice.
Ida S; Morino K; Sekine O; Ohashi N; Kume S; Chano T; Iwasaki K; Harada N; Inagaki N; Ugi S; Maegawa H
Diabetologia; 2017 Sep; 60(9):1761-1769. PubMed ID: 28642969
[TBL] [Abstract][Full Text] [Related]
30. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
31. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
32. Sustained
Tan EP; McGreal SR; Graw S; Tessman R; Koppel SJ; Dhakal P; Zhang Z; Machacek M; Zachara NE; Koestler DC; Peterson KR; Thyfault JP; Swerdlow RH; Krishnamurthy P; DiTacchio L; Apte U; Slawson C
J Biol Chem; 2017 Sep; 292(36):14940-14962. PubMed ID: 28739801
[TBL] [Abstract][Full Text] [Related]
33. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
34. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response.
Beyer K; Normann L; Sendler M; Käding A; Heidecke CD; Partecke LI; von Bernstorff W
Pancreas; 2016 Mar; 45(3):401-8. PubMed ID: 26390425
[TBL] [Abstract][Full Text] [Related]
35. Cross regulation between mTOR signaling and O-GlcNAcylation.
Very N; Steenackers A; Dubuquoy C; Vermuse J; Dubuquoy L; Lefebvre T; El Yazidi-Belkoura I
J Bioenerg Biomembr; 2018 Jun; 50(3):213-222. PubMed ID: 29524020
[TBL] [Abstract][Full Text] [Related]
36. O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells.
Gu Y; Gao J; Han C; Zhang X; Liu H; Ma L; Sun X; Yu W
Mol Med Rep; 2014 Aug; 10(2):897-904. PubMed ID: 24865644
[TBL] [Abstract][Full Text] [Related]
37. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro.
Zhang N; Chen X
Biotechnol Appl Biochem; 2016 Nov; 63(6):841-851. PubMed ID: 26333304
[TBL] [Abstract][Full Text] [Related]
38.
Sekine H; Okazaki K; Kato K; Alam MM; Shima H; Katsuoka F; Tsujita T; Suzuki N; Kobayashi A; Igarashi K; Yamamoto M; Motohashi H
Mol Cell Biol; 2018 Sep; 38(17):. PubMed ID: 29941490
[TBL] [Abstract][Full Text] [Related]
39. O-linked β-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells.
Goldberg H; Whiteside C; Fantus IG
Am J Physiol Endocrinol Metab; 2011 Oct; 301(4):E713-26. PubMed ID: 21712532
[TBL] [Abstract][Full Text] [Related]
40.
Xu Z; Isaji T; Fukuda T; Wang Y; Gu J
J Biol Chem; 2019 Mar; 294(9):3117-3124. PubMed ID: 30587575
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
